Ipsen announces new data on Dysport in neurological disease
Dysport reduces muscle contractions by blocking the transmission of nerve impulses
Read More
Tag: Ipsen
Genfit and Ipsen announce elafibranor results
ELATIVE, a randomised PBC trial involving 161 patients, has successfully met its primary endpoint
Read More
Ipsen reacts to NICE’s Cabometyx verdict
Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group
Read More
Positive results for Ipsen’s Cabometyx in combination with nivolumab
Benefits were identified with Cabometyx in combination with nivolumab across all efficacy measures
Read More
Positive results for Ipsen’s metastatic pancreatic cancer treatment
Onivyde regimen demonstrated statistically significant improvement in overall survival
Read More
Ipsen and Marengo Therapeutics announce strategic partnership
Deal will advance precision immuno-oncology candidates from Marengo’s STAR platform
Read More
Ipsen launches new self-injection Somatuline option
Good news for adult patients with gastroenteropancreatic neuroendocrine tumours.
Read More
Ipsen acquires Clementia in bid to boost rare disease portfolio
Ipsen has announced plans to acquire Clementia Pharmaceuticals.
Read More
Ipsen’s Cabometyx wins EU nod for liver cancer
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Read More
NICE u-turn recommends Ipsen’s Cabometyx for kidney cancer
NHS funding for Ipsen’s Cabometyx is now being recommended by the National Institute for Health and Care Excellence to treat kidney cancer.
Read More
NICE rules against first-line use of Ipsen’s Cabometyx
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Read More
EU OKs first-line use of Ipsen’s Cabometyx
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
